Key result
Metabolic drugs like dichloroacetate may partially restore RV function via glucose oxidation, pending clinical validation.
Why the study?
The metabolic shift from oxidative mitochondrial metabolism to glycolysis during right ventricular remodeling in pulmonary arterial hypertension and its therapeutic modulation remain to be fully understood.
Population
Patients with pulmonary arterial hypertension and right ventricular remodeling and animal models of right ventricular failure
Comparison
Metabolic targeting drugs including PDK inhibitors and partial inhibitors of fatty acid oxidation
Design
Review
Authors
Loading...
May not change RV failure management; hypothesis-generating for metabolic modulation in pulmonary hypertension.
Targeting the metabolic shift from mitochondrial oxidation to glycolysis in right ventricular remodeling presents a potential therapeutic strategy for pulmonary arterial hypertension, though clinical benefits remain to be established.
Zhang et al. (2016) conducted a review in Pulmonary arterial hypertension and right ventricular remodeling. Metabolic targeting drugs (e.g., Dichloroacetate) was evaluated. Metabolic targeting drugs like Dichloroacetate may partially restore right ventricular structure and function by promoting glucose oxidation, though clinical benefits remain to be determined.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: